Clinical Trials Arena on MSN
Novartis’ RemIND trial of oral remibrutinib meets primary endpoint
The trial is assessing remibrutinib's safety, tolerability and efficacy in adults with CIndU unresponsive to ...
Phase 3 trial results show remibrutinib significantly improves complete response rates in patients with 3 types of chronic inducible urticaria.
Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...
Novartis AG AG on Wednesday released positive topline results from its pivotal Phase 3 RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU). The Disease The primary endpoint was ...
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib, a highly selective oral BTK inhibitor, was ...
Novartis is on course to expand the label for its recently approved oral BTK inhibitor Rhapsido, after chalking up a win in chronic skin disorder chronic inducible urticaria (CINDU).
Novartis reports positive topline results from pivotal phase III RemIND trial of oral remibrutinib in chronic inducible urticaria: Basel Thursday, February 19, 2026, 13:00 Hrs [IS ...
Swiss pharma giant Novartis has announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU).
BOSTON -- Treatment with an investigational anti-KIT monoclonal antibody induced clinically meaningful responses in the two most common forms of chronic inducible urticaria, a dose-ranging phase II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results